Chairperson: M. Quintel
Speakers: D. Chiumello, L. Gattinoni, M. Maggiorini
During this webinar we will analyze the potential of minimally invasive extracorporeal CO2 removal (LF-ECCO2-R). Starting from concepts of respiratory pathophysiology, we will discuss the differences between a lung in the clinical context defined as ARDS and in COVID-19 disease, and try to identify the best patient-tailored ventilatory strategies. The rationale and potential for a well-designed minimally invasive extracorporeal CO2 removal system in the management of the patient’s ventilatory support will then be analyzed in order to choose the best setting to prevent ventilator induced lung injury (VILI).
Clinical experiences of applying the minimally invasive CO2 removal system both in the context of certain forms of ARDS and COVID-19 too will be described. Finally we will reflect on the fact that commonly accepted definitions like ARDS and general flowcharts adopted for its management may not necessarily always represent the best strategy for all patients, included in the COVID-19 context.
Supported bySIGN UP TO WATCH